Almirall partner MC2 on the verge of EU victory after ten years of hard work

The fact that MC2 therapeutics is close to its EU and US launch for the psoriasis treatment Wynzora is a significant milestone, says CEO Jesper Lange.
Photo: MC2 Therapeutics / PR
Photo: MC2 Therapeutics / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

On Tuesday, MC2 Therapeutics and its partner Almirall announced that they had completed the EU decentralized procedure for the psoriasis treatment Wynzora, which is the last step before individual the health authorities in individual European countries can start issuing marketing authorizations.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading